Dystrophic epidermolysis bullosa: pathogenesis and clinical features.
Dystrophic epidermolysis bullosa (DEB) is relatively well understood. Potential therapies are in development. This article describes the pathogenesis and clinical features of DEB. It also describes therapeutic options and the future of molecular therapies.
Bruckner-Tuderman
Leena
L
Department of Dermatology, University Medical Center Freiburg, Hauptstrasse 7, 79104 Freiburg, Germany. bruckner-tuderman@uniklinik-freiburg.de
D020405:Dermis / Q000473:pathology*; D004817:Epidermis / Q000473:pathology*; D016108:Epidermolysis Bullosa Dystrophica / Q000209:etiology* / Q000473:pathology* / Q000628:therapy; D006801:Humans